VLON - Vallon Pharma secures new European patent for ADAIR

Vallon Pharmaceuticals ([[VLON]] -6.1%) announces that the European Patent Office has issued patent number EP3576719B1 covering ADAIR, the Company’s proprietary abuse-deterrent formulation of immediate-release dextroamphetamine.The new European patent covers composition of matter and method of use for ADAIR, with a base patent term extending until 2038.ADAIR was previously granted two patents in U.S. with a base patent term extending until 2037, excluding patent term extensions. ADAIR is being developed for Europe and the U.K. through a license and collaboration agreement with MEDICE Arzneimittel Pütter GmbH.Under the terms of the agreement, Vallon will receive development and sales milestone payments and double-digit sales-based royalty payments.

For further details see:

Vallon Pharma secures new European patent for ADAIR